Table 12.

Seventeen interaction and non-interaction predictions made by the DIKB using the evidence-board’s belief criteria strategy.

Pair	Prediction	AUCi/AUC‡
diltiazem - midazolam*	$\frac{{\mathit{AUC}}_i}{\mathit{AUC}}>2$	≥ 3
diltiazem - triazolam*	$\frac{{\mathit{AUC}}_i}{\mathit{AUC}}>2$	2.83
midazolam* - clarithromycin	$\frac{{\mathit{AUC}}_i}{\mathit{AUC}}>2$	≥ 7
midazolam* - erythromycin	$\frac{{\mathit{AUC}}_i}{\mathit{AUC}}>2$	4.4
midazolam* - fluconazole	$\frac{{\mathit{AUC}}_i}{\mathit{AUC}}>2$	≥ 2.6
midazolam* - itraconazole	$\frac{{\mathit{AUC}}_i}{\mathit{AUC}}>2$	10.8
midazolam* - ketoconazole	$\frac{{\mathit{AUC}}_i}{\mathit{AUC}}>2$	15.9
midazolam* - nefazodone	$\frac{{\mathit{AUC}}_i}{\mathit{AUC}}>2$	4.6
triazolam* - clarithromycin	$\frac{{\mathit{AUC}}_i}{\mathit{AUC}}>2$	5.3
triazolam* - erythromycin	$\frac{{\mathit{AUC}}_i}{\mathit{AUC}}>2$	2.1
triazolam* - fluconazole	$\frac{{\mathit{AUC}}_i}{\mathit{AUC}}>2$	2.5
triazolam* - itraconazole	$\frac{{\mathit{AUC}}_i}{\mathit{AUC}}>2$	≥ 3.1
triazolam* - ketoconazole	$\frac{{\mathit{AUC}}_i}{\mathit{AUC}}>2$	≥ 9.2
triazolam* - nefazodone	$\frac{{\mathit{AUC}}_i}{\mathit{AUC}}>2$	≥ 3.9
triazolam* - atorvastatin †	$\frac{{\mathit{AUC}}_i}{\mathit{AUC}}>2$	n/a
triazolam - simvastatin †	no interaction	n/a
triazolam - β-OH-simvastatin †	no interaction	n/a

Asterisks indicate the drug or drug metabolite that the system predicts will be the object of the interaction. The DIKB makes interaction predictions at three levels representing the anticipated AUC ratio of the DDI’s object drug: $\frac{{\mathit{AUC}}_i}{\mathit{AUC}}=(0,1.3)$, $\frac{{\mathit{AUC}}_i}{\mathit{AUC}}=[1.3,2)$, and $\frac{{\mathit{AUC}}_i}{\mathit{AUC}}>2$.

^†a pair classified as “unknown” in the validation set.

^‡AUC ratios present in at least one evidence item in the validation set that supports the interaction.